Although epithelial ovarian cancer is a relatively chemosensitive disease, the disease ultimately relapses and leads to the death of most patients. The median duration of remission following first-line chemotherapy with platinum/taxane combinations for patients with advanced disease is between 12 and 24 months. A variety of strategies have been employed to maintain the benefits achieved with chemotherapy in advanced ovarian cancer. The dose and duration of chemotherapy have both been increased, but increases in response rates have not been associated with improvement in survival ([Eltabbakh *et al*, 1998](#bib5){ref-type="other"}; [Umesaki *et al*, 1999](#bib14){ref-type="other"}; [McGuire, 2000](#bib10){ref-type="other"}).

The concept of additional therapy to maintain the response achieved with chemotherapy has been assessed in a number of disease and clinical settings. In the 1980s, interferon-alpha (INF*α*) was assessed as a maintenance therapy for patients with multiple myeloma. As a single agent, interferon has a low response rate in myeloma patients with responses of approximately 15%. However, in patients who demonstrated no evidence of disease progression following primary chemotherapy, maintenance therapy with low-dose subcutaneous INF*α* improved progression-free and overall survival ([Mandelli *et al*, 1990](#bib8){ref-type="other"}).

Interferon-*α* has limited activity in active advanced ovarian cancer ([Freedman *et al*, 1983](#bib7){ref-type="other"}; [Einhorn *et al*, 1988](#bib4){ref-type="other"}). However, we hypothesised that subcutaneous INF*α* may act as an effective maintenance therapy in patients with advanced ovarian cancer and thus improve overall survival. To test this hypothesis, a prospective randomised trial was performed in patients with FIGO stage Ic--IV epithelial ovarian cancer, in whom no evidence of disease progression was seen following surgery and/or chemotherapy.

PATIENTS AND METHODS
====================

The study was approved by the Local Research Ethics Committee of each participating centre and written informed consent was obtained prior to randomisation. Patients eligible for the study had histologically proven epithelial ovarian cancer that showed no evidence of disease progression (on clinical, radiological or CA-125 assessment) following postoperative chemotherapy. Patients were randomised within 8 weeks of completing chemotherapy to treatment with INF-*α* 2a (Roferon-A, Roche) (4.5 mega-units subcutaneously 3 days per week) or to a no maintenance treatment control group. Interferon was continued until disease progression, or in response to toxicity or patient request. The study was designed to detect a 50% increase in median survival and therefore required 300 randomised patients. The trial profile is shown in [Figure 1](#fig1){ref-type="fig"}Figure 1Trial profile..

To further analyse the effect of maintenance interferon, the disease status of each patient was determined following surgery and/or chemotherapy. Patients in whom there was no evidence of disease either clinically or radiologically following surgery and/or chemotherapy were designated as disease-free (DF). Those patients in whom disease was apparent clinically or radiologically following surgery and/or chemotherapy were designated as disease-present (DP).

For additional detail regarding patient selection, dose modifications, study design and statistical methods, see [supplementary information](#sup1){ref-type="other"}.

RESULTS
=======

Between February 1990 and July 1997, 300 patients were randomised by 23 consultants from 14 centres across the UK (for participating centres and consultants, see [supplementary information](#sup1){ref-type="other"}), 151 to observation, 149 to interferon. The patients in the two treatment arms were similar with respect to baseline characteristics ([Table 1](#tbl1){ref-type="table"}Table 1Patient characteristics by treatment group **InterferonObservation** **(*n*=149)(*n*=149)***Median (range) age at diagnosis (years)*58 (31--76)57 (33--78)   *FIGO stage at diagnosis*   I11 (7%)12 (8%) II22 (14%)19 (13%) III94 (63%)95 (64%) IV22 (15%)23 (15%)   *Residual disease following surgery (cm)*   023 (18%)26 (20%) \<244 (35%)51 (40%) 2--524 (19%)13 (10%) \>536 (28%)40 (31%)   *Histology*   Serous67 (45%)72 (48%) Mucinous10 (7%)12 (8%) Endometrioid27 (18%)34 (23%) Clear cell4 (3%)4 (3%) Other20 (13%)10 (7%) Undifferentiated3 (2%)2 (1%) Not stated18 (12%)15 (10%)   *Tumour grade*   111 (9%)14 (11%) 247 (38%)43 (33%) 366 (53%)75 (57%) Not stated2517   *WHO performance status pre-chemotherapy*   084 (60%)83 (56%) 146 (32%)46 (31%) 27 (4%)17 (12%) 33 (2%)1 (1%) 43 (2%)0 Not stated62   *Chemotherapy regimen*   Platinum single agent89 (60%)88 (59%) Platinum combination44 (29%)37 (25%) Platinum/taxane15 (10%)20 (13%) Taxane single agent01 (1%) Other single agent1 (1%)3 (2%)   *Response to surgery and/or chemotherapy*   Disease free89 (61%)95 (65%) Disease present58 (39%)52 (35%) Not evaluable22   *CA125 after surgery and/or chemotherapy*   \<35 U ml^−1^47 (77%)62 (78%) 35--65 U ml^−1^2 (3%)9 (11%) 65--200 U ml^−1^8 (13%)5 (6%) \>2004 (7%)4 (5%) Not stated8869   *WHO performance status at randomisation*   0113 (76%)114 (79%) 132 (22%)28 (19%) 23 (2%)2 (1%) 300 400 Not stated15). The median follow-up time for interferon patients was 27.0 months (range 2.3--149.7), and for observation patients 32.2 months (range 1.7--141.7). Eight patients (two interferon and six observation) died without attending any follow-up visits. Of the 149 patients randomised to receive maintenance INF*α*, 144 received at least one injection (see [supplementary information](#sup1){ref-type="other"}). The duration of treatment and the reason for stopping is shown in [Table 2](#tbl2){ref-type="table"}Table 2Duration of interferon treatment and reason for stopping treatment **Number of patientsMedian (range) time (in months) on interferon***All patients*1445 (\<1--88)   *Interferon stopped*   Disease progression618 (1--66) Toxicity503 (\<1--37) Patient desire147 (\<1--48) Other838 (1--71) Death of patient48 (3--14) Not stated422 (7--51)*Treatment status unknown at last review*354 (51--88). [Figure 4](#fig4){ref-type="fig"} shows compliance with interferon maintenance over time in those patients who remained progression free. The most commonly reported toxicity/adverse event for both interferon and observation patients was fatigue (72 and 46%, respectively) ([Table 3](#tbl3){ref-type="table"}Table 3Adverse events/toxicity (all grades) **InterferonObservation**  **(*n*=144)(*n*=149)Significance**Toxicity/adverse event   Flu-like symptoms102 (69%)47 (31%)*P*\<0.001Fatigue106 (71%)71 (47%)*P*\<0.001Nausea/vomiting61 (41%)52 (34%)Not significant    Neurological6 (4%)NR---Dyspnoea9 (6%)NR---Depression/anxiety9 (6%)NR---Skin change/rash7 (5%)NR---Alopecia7 (5%)NR---Arthalgia/arthritis4 (3%)NR---Insomnia3 (2%)NR---Haematological3 (2%)NR---Hepatic1 (1%)NR---Injection site reaction2 (1%)NR---Other19 (13%)NR---Not stated4 (3%)NR---[^1]). Dose modification of interferon was made in 18 (12.5%) patients due to toxicity.

No benefit for interferon maintenance was seen in terms of either overall or clinical event-free survival. The median overall survival in the interferon arm was 27.0 months and in the observation arm 32.7 months. The median clinical event-free survival in the interferon arm was 10.3 months and 10.4 months in the observation arm. The Kaplan--Meier survival curves for overall and clinical event-free survival ([Figure 2](#fig2){ref-type="fig"}Figure 2Overall survival by randomised treatment group. and [Figure 3](#fig3){ref-type="fig"}Figure 3Clinical event-free survival by randomised treatment group.) showed no significant difference (overall survival -- unadjusted HR=1.06, 95% C.I.=0.82--1.38, Log-rank test *P*=0.65; clinical event-free survival -- unadjusted HR=0.96, 95% C.I.= 0.75--1.22, Log-rank test *P*=0.73). When hazard ratios were adjusted for prognostic factors previously defined, the results were similar.

The effect of treatment on overall survival and clinical event-free survival was compared separately among patients who were DF after surgery and/or chemotherapy and those who had DP after surgery and/or chemotherapy. This comparison was unplanned and performed only as a hypothesis generating analysis. No significant differences for interferon maintenance were identified (DF patients -- clinical event-free survival -- unadjusted HR=0.88, 95% C.I.=0.63--1.22).

The multivariate analysis of prognostic factors and treatment received, performed on the 298 patients in the intention to treat population ([Table 4](#tbl4){ref-type="table"}Table 4Multivariate analysis of treatment received and prognostic factors for overall and clinical event-free survival (*n*=298) **Overall survivalClinical event-free survival** **Adjusted HR (95% C.I.)*P*Adjusted HR (95% C.I.)*P****Randomised treatment*     Observation1.00 1.00  Interferon1.10 (0.83--1.45)0.510.92 (0.71--1.20)0.55     *Response--1° treatment*     Disease-free1.00 1.00  Disease-present1.53 (1.12--1.65)0.011.84 (1.37--2.49)\<0.001     *Age at diagnosis (years)*     \<551.00 1.00  55--651.51 (1.10--2.07) 1.13 (0.83--1.52)  \>651.36 (0.92--2.01)0.0341.14 (0.79--1.65)0.67     *FIGO stage*     Ic1.00 1.00  II0.80 (0.33--2.74) 1.02 (0.51--2.06)  III2.11 (1.04--4.29) 2.48 (1.28--4.80)  IV2.82 (1.32--6.03)\<0.0012.92 (1.42--5.59)\<0.001     *WHO performance status*     01.00 1.00  11.16 (0.82--1.65) 1.16 (0.82--1.65)  2/3/41.74 (1.22--2.49)0.0351.74 (1.22--2.49)0.62     *Size of residual disease*     01 1  \<2 cm1.02 (0.63--1.64) 1.02 (0.63--1.64)  \>2 cm1.10 (0.67--2.44) 1.09 (0.67--1.77)  Not stated1.69 (0.97--2.93)0.171.69 (0.97--2.93)0.74     *Tumour type*     Serous1.00 1.00  Mucinous1.32 (0.78--2.22) 1.15 (0.68--1.93)  Endometrioid1.16 (0.79--1.70) 1.06 (0.72--1.56)  Clear cell1.69 (0.65--4.41) 1.39 (0.49--3.93)  Other0.86 (0.53--1.40) 0.89 (0.56--1.43)  Undifferentiated1.09 (0.37--3.81) 1.36 (0.52--3.57)  Not stated1.59 (1.00--2.43)0.331.39 (0.87--2.21)0.74     *Tumour grade*     Well  differentiated1.00 1.00  Moderately differentiated0.83 (0.45--1.54) 0.87 (0.54--1.52)  Poorly differentiated1.33 (0.73--2.41) 1.32 (0.77--2.24)  Not stated0.92 (0.46--1.84)0.0330.85 (0.45--1.60)0.038), demonstrated that receiving interferon maintenance was not related to either overall or clinical event-free survival (see [supplementary information](#sup1){ref-type="other"}).

DISCUSSION
==========

This trial was designed to determine whether the use of low-dose subcutaneous INF*α* could improve the overall survival of patients with epithelial ovarian cancer following primary therapy with surgery and/or chemotherapy. Patients with all stages of disease at presentation and with no evidence of disease progression after primary therapy were randomised within the trial. The overall and clinical event-free survival of ovarian cancer patients studied within this trial was typical of results obtained with platinum combination chemotherapy in the 1990s. However, survival times were not improved by the addition of maintenance low-dose subcutaneous IFN*α* following primary therapy.

Interferon-*α* has been shown to have an *in vitro* activity against ovarian cancer cell lines ([Epstein *et al*, 1980](#bib6){ref-type="other"}) and a limited clinical benefit in advanced ovarian cancer ([Freedman *et al*, 1983](#bib7){ref-type="other"}; [Einhorn *et al*, 1988](#bib4){ref-type="other"}). Clinical studies have assessed the effect of intraperitoneal INF*α* in a number of phase II studies both after and in combination with platinum chemotherapy ([Berek *et al*, 1985](#bib1){ref-type="other"}; [Nardi *et al*, 1990](#bib11){ref-type="other"}; [Willemse *et al*, 1990](#bib15){ref-type="other"}; [Bruzzone *et al*, 1997](#bib3){ref-type="other"}; [Berek *et al*, 1999](#bib2){ref-type="other"}). These studies have confirmed that such a treatment can be delivered although its benefit over standard treatment has not been assessed. No clinical trial of subcutaneous INF*α* in ovarian cancer has previously been reported. However, an alternative immunoregulatory cytokine, interferon-*γ* has been assessed in a randomised phase III trial as an addition to primary chemotherapy with cisplatin and cylophosphamide ([Windbichler *et al*, 2000](#bib16){ref-type="other"}). This showed a significant improvement in progression-free survival. However, improvements in clinical response rate and overall survival did not achieve statistical significance.

Experience with biological therapy has suggested that the benefits of such therapy are often seen in patients with small volume or clinically undetectable disease. Although this effect has also been seen in previous trials of cytokine therapy in ovarian cancer ([Berek *et al*, 1985](#bib1){ref-type="other"}; [Pujade-Lauraine *et al*, 1996](#bib12){ref-type="other"}), the recent study of interferon-*γ* showed equal efficacy in patients with both small and large volume disease ([Windbichler *et al*, 2000](#bib16){ref-type="other"}). To mirror the initial study of interferon maintenance in myeloma, patients with no evidence of disease progression following primary therapy were randomised and therefore, many patients with residual disease were randomised. However, a subgroup analysis of the patients in complete clinical remission within this study failed to identify a significant benefit for those patients.

Compliance with interferon maintenance was poor ([Figure 4](#fig4){ref-type="fig"}Figure 4Compliance with interferon maintenance. The percentage of patients still receiving interferon in the absence of disease progression is shown.). At 6 months, only 67% of patients with no evidence of disease progression remained on interferon maintenance. This is likely to be due to the fact that this cohort of patients had undergone both surgical intervention and chemotherapy prior to commencing interferon treatment. This is in contrast to studies in myeloma, renal cancer and melanoma in which treatment rarely follows both extensive surgery and chemotherapy. Pegylated interferon has recently been introduced into clinical trials. The half-life of these modified forms of interferon are significantly increased allowing weekly administration. It may be that the use of such treatment would improve compliance by reducing both the frequency of administration and the toxicity associated with the treatment.

Despite modern chemotherapy combinations, the natural history of ovarian carcinoma remains one of relapse following initial response to chemotherapy. A potential benefit for maintenance paclitaxel chemotherapy for some patients with ovarian cancer has recently been reported although at the cost of clinically significant toxicity ([Markman *et al*, 2003](#bib9){ref-type="other"}). The need for an effective nontoxic maintenance therapy is clear. This study has demonstrated that subcutaneous INF-*α* given following surgery and chemotherapy is not the answer to this ongoing dilemma. However, the recent development of new, targeted molecular therapies may allow the concept of maintenance therapy to be examined further.
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